Yahoo Finance

Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best small cap AI stocks to buy according to analysts. On July 8, Rallybio Corporation (NASDAQ:RLYB) announced a definitive agreement to sell ...
Yahoo Finance

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...
Seeking Alpha

Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...
BetaKit

After buying Cyclica and Valence, Recursion secures $50 million USD from Nvidia for AI drug discovery

Computing giant Nvidia has invested $50 million USD in Recursion to fuel the development of its artificial intelligence (AI) drug-discovery technology, as part of a deal that will see the two United ...
Seeking Alpha

Recursion: Lack Of Near-Term Catalysts Leaves The Stock Vulnerable

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...
The Motley Fool

Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock?

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...